Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome

Maurizio Averna, Amy O. Johnson-Levonas, Helena Vaverkova, Michel Farnier, Luc Missault, Margus Viigimaa, Philippe Brudi, Arvind Shah, William Taggart, Qian Dong

Risultato della ricerca: Article

8 Citazioni (Scopus)

Abstract

Metabolic syndrome (MetS) is a clustering of atherosclerotic coronary heart disease risk factors. This post-hoc analysis compared the effects of switching to ezetimibe/simvastatin 10/20 mg or rosuvastatin 10 mg in a cohort of 618 high-risk hypercholesterolaemic patients with (n=368) and without (n=217) MetS who had previously been on statin monotherapy. Patients were randomised 1:1 to double-blind ezetimibe/simvastatin 10/20 mg or rosuvastatin 10 mg for 6 weeks. Least squares mean percent change from baseline and 95% confidence intervals in lipid efficacy parameters were calculated for the population and within subgroups. Treatment with ezetimibe/simvastatin was significantly more effective than rosuvastatin at lowering low-density lipoprotein cholesterol, total cholesterol, non- high-density lipoprotein cholesterol, and apolipoprotein B (all p<0.001). No significant differences in treatment effects were seen between the presence and absence of MetS. In this post-hoc analysis of high-risk hypercholesterolaemic patients the lipid-reducing effects of ezetimibe/simvastatin or rosuvastatin were not altered significantly by the presence of MetS.
Lingua originaleEnglish
pagine (da-a)262-270
Numero di pagine9
RivistaDIABETES & VASCULAR DISEASE RESEARCH
Volume8
Stato di pubblicazionePublished - 2011

Fingerprint

Simvastatin
Lipids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Apolipoproteins B
Least-Squares Analysis
LDL Cholesterol
HDL Cholesterol
Coronary Disease
Cluster Analysis
Cholesterol
Confidence Intervals
Ezetimibe
Rosuvastatin Calcium
Therapeutics
Population

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism

Cita questo

Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome. / Averna, Maurizio; Johnson-Levonas, Amy O.; Vaverkova, Helena; Farnier, Michel; Missault, Luc; Viigimaa, Margus; Brudi, Philippe; Shah, Arvind; Taggart, William; Dong, Qian.

In: DIABETES & VASCULAR DISEASE RESEARCH, Vol. 8, 2011, pag. 262-270.

Risultato della ricerca: Article

Averna, M, Johnson-Levonas, AO, Vaverkova, H, Farnier, M, Missault, L, Viigimaa, M, Brudi, P, Shah, A, Taggart, W & Dong, Q 2011, 'Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome', DIABETES & VASCULAR DISEASE RESEARCH, vol. 8, pagg. 262-270.
Averna, Maurizio ; Johnson-Levonas, Amy O. ; Vaverkova, Helena ; Farnier, Michel ; Missault, Luc ; Viigimaa, Margus ; Brudi, Philippe ; Shah, Arvind ; Taggart, William ; Dong, Qian. / Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome. In: DIABETES & VASCULAR DISEASE RESEARCH. 2011 ; Vol. 8. pagg. 262-270.
@article{15c9721558434dbf88a1e0fd93e02f0b,
title = "Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome",
abstract = "Metabolic syndrome (MetS) is a clustering of atherosclerotic coronary heart disease risk factors. This post-hoc analysis compared the effects of switching to ezetimibe/simvastatin 10/20 mg or rosuvastatin 10 mg in a cohort of 618 high-risk hypercholesterolaemic patients with (n=368) and without (n=217) MetS who had previously been on statin monotherapy. Patients were randomised 1:1 to double-blind ezetimibe/simvastatin 10/20 mg or rosuvastatin 10 mg for 6 weeks. Least squares mean percent change from baseline and 95{\%} confidence intervals in lipid efficacy parameters were calculated for the population and within subgroups. Treatment with ezetimibe/simvastatin was significantly more effective than rosuvastatin at lowering low-density lipoprotein cholesterol, total cholesterol, non- high-density lipoprotein cholesterol, and apolipoprotein B (all p<0.001). No significant differences in treatment effects were seen between the presence and absence of MetS. In this post-hoc analysis of high-risk hypercholesterolaemic patients the lipid-reducing effects of ezetimibe/simvastatin or rosuvastatin were not altered significantly by the presence of MetS.",
author = "Maurizio Averna and Johnson-Levonas, {Amy O.} and Helena Vaverkova and Michel Farnier and Luc Missault and Margus Viigimaa and Philippe Brudi and Arvind Shah and William Taggart and Qian Dong",
year = "2011",
language = "English",
volume = "8",
pages = "262--270",
journal = "Diabetes and Vascular Disease Research",
issn = "1479-1641",
publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome

AU - Averna, Maurizio

AU - Johnson-Levonas, Amy O.

AU - Vaverkova, Helena

AU - Farnier, Michel

AU - Missault, Luc

AU - Viigimaa, Margus

AU - Brudi, Philippe

AU - Shah, Arvind

AU - Taggart, William

AU - Dong, Qian

PY - 2011

Y1 - 2011

N2 - Metabolic syndrome (MetS) is a clustering of atherosclerotic coronary heart disease risk factors. This post-hoc analysis compared the effects of switching to ezetimibe/simvastatin 10/20 mg or rosuvastatin 10 mg in a cohort of 618 high-risk hypercholesterolaemic patients with (n=368) and without (n=217) MetS who had previously been on statin monotherapy. Patients were randomised 1:1 to double-blind ezetimibe/simvastatin 10/20 mg or rosuvastatin 10 mg for 6 weeks. Least squares mean percent change from baseline and 95% confidence intervals in lipid efficacy parameters were calculated for the population and within subgroups. Treatment with ezetimibe/simvastatin was significantly more effective than rosuvastatin at lowering low-density lipoprotein cholesterol, total cholesterol, non- high-density lipoprotein cholesterol, and apolipoprotein B (all p<0.001). No significant differences in treatment effects were seen between the presence and absence of MetS. In this post-hoc analysis of high-risk hypercholesterolaemic patients the lipid-reducing effects of ezetimibe/simvastatin or rosuvastatin were not altered significantly by the presence of MetS.

AB - Metabolic syndrome (MetS) is a clustering of atherosclerotic coronary heart disease risk factors. This post-hoc analysis compared the effects of switching to ezetimibe/simvastatin 10/20 mg or rosuvastatin 10 mg in a cohort of 618 high-risk hypercholesterolaemic patients with (n=368) and without (n=217) MetS who had previously been on statin monotherapy. Patients were randomised 1:1 to double-blind ezetimibe/simvastatin 10/20 mg or rosuvastatin 10 mg for 6 weeks. Least squares mean percent change from baseline and 95% confidence intervals in lipid efficacy parameters were calculated for the population and within subgroups. Treatment with ezetimibe/simvastatin was significantly more effective than rosuvastatin at lowering low-density lipoprotein cholesterol, total cholesterol, non- high-density lipoprotein cholesterol, and apolipoprotein B (all p<0.001). No significant differences in treatment effects were seen between the presence and absence of MetS. In this post-hoc analysis of high-risk hypercholesterolaemic patients the lipid-reducing effects of ezetimibe/simvastatin or rosuvastatin were not altered significantly by the presence of MetS.

UR - http://hdl.handle.net/10447/74494

M3 - Article

VL - 8

SP - 262

EP - 270

JO - Diabetes and Vascular Disease Research

JF - Diabetes and Vascular Disease Research

SN - 1479-1641

ER -